Drug news
Afinitor (Novartis) fails Gastric Cancer study
Novartis reported the results of the 656 patient GRANITE-1 Phase III randomised, double-blind, multicentre study which showed that Afinitor (everolimus) monotherapy did not significantly improve overall survival in patients with advanced Gastric Cancer who had previously been treated with one or two lines of systemic chemotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.